Zoetis Inc Cl A (ZTS) Stock Price, Quote & News

Company Profile

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermato...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 973 822 7000

Website: www.zoetis.com

Address:

10 Sylvan Way, Parsippany, United States

Lackcaps Feb. 26 at 6:34 AM

$ZTS Animal health pharmaceuticals

0 · Reply

MyChicago Feb. 25 at 6:09 PM

$ZOMDF $WOOF $ZTS $HOOD $ELAN

0 · Reply

SW6 Feb. 18 at 8:59 PM

$ZTS

0 · Reply

Ripera Feb. 17 at 2:44 PM

$ZTS holding above 124.15 50DMA with EPS 6.02, I’m long for a trend crawl

0 · Reply

ZacksResearch Feb. 12 at 3:53 PM

$ZTS posts a solid Q4 earnings beat — what's driving the gains? Zoetis delivered Q4 adjusted EPS of $1.48, topping the Zacks Consensus Estimate of $1.40, with total revenues up 3% in the reported quarter to $2.39B. Revenues in the International segment increased 8% year over year on a reported basis, driven by strength in companion animal sales. Discover why ZTS is rallying post-earnings 👉 https://www.zacks.com/stock/news/2862520/zoetis-stock-gains-after-q4-earnings-revenues-beat-estimates?cid=sm-stocktwits-2-2862520-body-33308&ADID=SYND_STOCKTWITS_TWEET_2_2862520_BODY_33308

0 · Reply

AStrokeOfLuck Feb. 12 at 3:36 PM

$ZTS

0 · Reply

ZacksResearch Feb. 12 at 2:53 PM

$ZTS just delivered the kind of quarter bulls love Zoetis topped Q4 earnings and revenue estimates, sending the stock higher, as strong international growth and upbeat 2026 guidance helped offset softness in the U.S. That’s resilience with a forward-looking tailwind. Does this momentum have legs into 2026? Get the full breakdown here 👉 https://www.zacks.com/stock/news/2862520/zoetis-stock-gains-after-q4-earnings-revenues-beat-estimates?cid=sm-stocktwits-2-2862520-teaser-33286&ADID=SYND_STOCKTWITS_TWEET_2_2862520_TEASER_33286

0 · Reply

Bogeymakr Feb. 12 at 2:18 PM

$ZTS

0 · Reply

Bazzzigar Feb. 12 at 2:16 PM

$ZTS as expected

0 · Reply

OpenOutcrier Feb. 12 at 1:32 PM

$ZTS (+2.6% pre) Zoetis: Q4 Earnings Snapshot https://ooc.bz/l/93125

0 · Reply

Zoetis to Participate in the Bank of America Securities 2026 Animal Health Summit

Feb 16, 2026, 10:58 AM EST - 9 days ago

Impax U.S. Sustainable Economy Fund Q4 2025 Contributors And Detractors

AMD GOOG LLY MRK ORCL

Feb 16, 2026, 8:15 AM EST - 9 days ago

Zoetis: Why I'm Doubling Down On My Worst 2025 Pick

Feb 12, 2026, 1:24 PM EST - 13 days ago

Analysts Question Zoetis' Pathway To Growth As Key Segments Slide

Feb 12, 2026, 12:44 PM EST - 13 days ago

Zoetis Inc. (ZTS) Q4 2025 Earnings Call Transcript

Feb 12, 2026, 8:33 AM EST - 13 days ago

Zoetis forecasts strong 2026 profit, revenue on steady pet‑medicine demand

Feb 12, 2026, 7:00 AM EST - 13 days ago

Zoetis Reports Fourth Quarter and Full Year 2025 Results

Feb 12, 2026, 2:12 AM EST - 14 days ago

Top Wall Street Forecasters Revamp Zoetis Expectations Ahead Of Q4 Earnings

Feb 5, 2026, 4:15 PM EST - 20 days ago

Zoetis Declares Second Quarter 2026 Dividend

Jan 29, 2026, 9:39 AM EST - 27 days ago

Artisan Global Opportunities Fund Q4 2025 Portfolio Update

ARGX BKR BSX COF COIN INSM LEG

Jan 24, 2026, 8:00 AM EST - 4 weeks ago

Zoetis: Undervalued And Oversold

Jan 14, 2026, 8:22 AM EST - 6 weeks ago

Zoetis: Cheap Valuation And Attractive Product Launch Pipeline

Jan 12, 2026, 4:05 PM EST - 6 weeks ago

Zoetis Inc. (ZTS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 7, 2026, 1:49 PM EST - 7 weeks ago

Trade Tracker: Stephanie Link sells Eaton and buys more Zoetis, Natera

ETN NTRA

Dec 30, 2025, 8:30 AM EST - 2 months ago

Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2025 Financial Results

Dec 29, 2025, 9:59 AM EST - 2 months ago

These stocks fell hard in 2025, but analysts see as much as 65% upside for them in 2026

ACN ADBE ALGN CARR CMG CPRT EIX

Dec 23, 2025, 4:04 PM EST - 2 months ago

Trade Tracker: Stephanie Link buys mores Zoetis

Dec 18, 2025, 8:30 AM EST - 2 months ago

Zoetis to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 16, 2025, 1:15 AM EST - 2 months ago

Zoetis Announces Pricing of $1.75 Billion Convertible Senior Notes Offering

Dec 15, 2025, 7:09 AM EST - 2 months ago

Zoetis Announces Proposed $1.75 Billion Convertible Senior Notes Offering

Dec 15, 2025, 6:47 AM EST - 2 months ago

Gabelli Pet Parents' Fund Q3 2025 Contributors And Detractors

CHWY CVS FRPT TRUP WOOF

Dec 11, 2025, 4:15 PM EST - 2 months ago

Zoetis Declares First Quarter 2026 Dividend; Board Approves 6% Payment Increase

Dec 8, 2025, 9:03 PM EST - 2 months ago

Top 50 High-Quality Dividend Growth Stocks For December 2025

ACN ALLE APH DHI DPZ FDS GGG

Dec 5, 2025, 8:30 AM EST - 2 months ago

Zoetis Receives Health Canada Approval for Portela™(relfovetmab injection) to Alleviate Pain Associated with Osteoarthritis in Cats

Dec 4, 2025, 2:08 PM EST - 2 months ago

Zoetis Inc. (ZTS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 2, 2025, 11:43 AM EST - 3 months ago

Zoetis Inc. (ZTS) Discusses R&D Pipeline Progress and Strategic Vision in Animal Health Innovation Transcript

Dec 2, 2025, 7:30 AM EST - 3 months ago

Zoetis Highlights R&D Leadership and Long-Term Growth Opportunity at Innovation Webcast

Dec 2, 2025, 5:35 AM EST - 3 months ago

Top 15 High-Growth Dividend Stocks For December 2025

ACN ADP BMI DPZ EOG INTU MSCI

Nov 26, 2025, 4:15 PM EST - 3 months ago

Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs

Nov 21, 2025, 12:24 PM EST - 3 months ago

Zoetis Osteoarthritis Pain Franchise Needs A Reset: Analyst

Nov 20, 2025, 8:30 AM EST - 3 months ago

Zoetis to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 19, 2025, 8:30 AM EST - 3 months ago

Zoetis to Host Innovation Webcast

Nov 17, 2025, 11:24 AM EST - 3 months ago

These stocks have been hit hard in 2025 but could surge by as much as 57% from here

ADBE ALGN BLDR CARR CMG CPRT CRM

Nov 14, 2025, 11:35 AM EST - 3 months ago

Zoetis: A High-Quality Compounder Now On Sale?

Nov 7, 2025, 12:01 PM EST - 3 months ago

Zoetis: Why I'm Still Holding The Stock But Advise Against New Positions

Nov 6, 2025, 9:36 AM EST - 3 months ago

Zoetis Remains A Strong Buy Following Market Overreaction To Q3 Earnings

Nov 4, 2025, 4:16 PM EST - 4 months ago

Zoetis Inc. (ZTS) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 1:15 PM EST - 4 months ago

Zoetis Stock Outlook Clouded By Rising Competitive Pressures

Nov 4, 2025, 12:41 PM EST - 4 months ago

Zoetis: No Longer A Growth Stock

Nov 4, 2025, 8:59 AM EST - 4 months ago

This Animal Health Stock Tanks on Earnings. Pig and Chicken Medication Revenue Slumps.

Nov 4, 2025, 7:44 AM EST - 4 months ago

Zoetis trims annual revenue forecast on muted demand for animal treatments, shares slide

Nov 4, 2025, 7:00 AM EST - 4 months ago

Zoetis Announces Third Quarter 2025 Results

Nov 3, 2025, 4:15 PM EST - 4 months ago

Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026

Nov 3, 2025, 9:30 AM EST - 4 months ago

Zoetis: High-Quality Compounder For Patient Long-Term Dividend Growth Investors

Oct 31, 2025, 10:10 AM EDT - 4 months ago

Buy Zoetis Stock Today?

Oct 29, 2025, 8:30 AM EDT - 4 months ago

Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats

Oct 28, 2025, 8:30 AM EDT - 4 months ago

Zoetis Appoints Stephanie Tilenius to its Board of Directors

Oct 21, 2025, 6:48 AM EDT - 4 months ago

Zoetis Stock: Outlook Remains Muted

Oct 15, 2025, 7:00 AM EDT - 4 months ago

Zoetis Announces Health Canada Approval of Lenivia® (izenivetmab injection) for Alleviation of Osteoarthritis (OA) Pain in Dogs

Oct 10, 2025, 4:15 PM EDT - 4 months ago

Zoetis Receives Positive Opinion from CVMP for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs

Lackcaps Feb. 26 at 6:34 AM

$ZTS Animal health pharmaceuticals

0 · Reply

MyChicago Feb. 25 at 6:09 PM

$ZOMDF $WOOF $ZTS $HOOD $ELAN

0 · Reply

SW6 Feb. 18 at 8:59 PM

$ZTS

0 · Reply

Ripera Feb. 17 at 2:44 PM

$ZTS holding above 124.15 50DMA with EPS 6.02, I’m long for a trend crawl

0 · Reply

ZacksResearch Feb. 12 at 3:53 PM

0 · Reply

AStrokeOfLuck Feb. 12 at 3:36 PM

$ZTS

0 · Reply

ZacksResearch Feb. 12 at 2:53 PM

0 · Reply

Bogeymakr Feb. 12 at 2:18 PM

$ZTS

0 · Reply

Bazzzigar Feb. 12 at 2:16 PM

$ZTS as expected

0 · Reply

OpenOutcrier Feb. 12 at 1:32 PM

$ZTS (+2.6% pre) Zoetis: Q4 Earnings Snapshot https://ooc.bz/l/93125

0 · Reply

StocktwitsEarnings Feb. 12 at 12:11 PM

$ZTS Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $1.38 up 6.98% YoY • Reported revenue of $2.39B up 3.02% YoY • Zoetis provides full year 2026 revenue guidance of $9.83B to $10.03B, with diluted EPS of $6.65 to $6.75 on a reported basis, or $7.00 to $7.10 on an adjusted basis.

0 · Reply

DonCorleone77 Feb. 12 at 3:32 AM

$HWM $ZTS $QSR $H $CROX Some notable companies reporting before tomorrow's open, with earnings consensus estimates: - Howmet Aerospace (HWM), consensus 97c - Zoetis (ZTS), consensus $1.40 - Restaurant Brands (QSR), consensus 95c - US Foods (USFD), consensus $1.01 - Hyatt (H), consensus 34c - TransUnion (TRU), consensus $1.03 - Baxter International (BAX), consensus 54c - Crocs (CROX), consensus $1.91 - TripAdvisor (TRIP), consensus 13c

1 · Reply

NorthStarStats Feb. 12 at 2:10 AM

For anyone following along, I developed a Python-based statistical scanner to identify stocks with near-term institutional accumulation and upward price momentum. $ZTS (100), $ZBRA (98), $BMRN (97), $UHS (95), $MKTX (95),

0 · Reply

cubie Feb. 11 at 9:06 PM

earnings Before Bell so Place ur Bets: $NBIS 75 or 95 (100) $ZBRA 220 or 280 $CROX (65) 70 or $95 (100) $ZTS 115 or 142s $BTDR $9 or $13?

0 · Reply

ZacksResearch Feb. 9 at 3:55 PM

$ZTS is expected to potentially beat Q4 earnings expectations. With an Earnings ESP of +0.84% and a Zacks Rank #3, Zoetis is anticipated to deliver a strong performance. The company's diversified portfolio, especially in companion animal products like Simparica Trio and Apoquel, is expected to drive growth, despite challenges in certain segments. Discover more about what's fueling this outlook here 👉 https://www.zacks.com/stock/news/2841564/zoetis-gears-up-to-report-q4-earnings-heres-what-to-expect?cid=sm-stocktwits-2-2841564-body-32586&ADID=SYND_STOCKTWITS_TWEET_2_2841564_BODY_32586

0 · Reply

ZacksResearch Feb. 9 at 2:55 PM

$ZTS heading into Q4 earnings — beat setup or regional tug-of-war? The company is set up for a Q4 earnings beat, driven by strong international companion animal products sales, even as weaker U.S. demand weighs on overall results. Find out what this means for the stock 👉 https://www.zacks.com/stock/news/2841564/zoetis-gears-up-to-report-q4-earnings-heres-what-to-expect?cid=sm-stocktwits-2-2841564-teaser-32570&ADID=SYND_STOCKTWITS_TWEET_2_2841564_TEASER_32570

0 · Reply

Dividendology Feb. 6 at 3:39 PM

I'm a big believer in buying 'high quality' stocks. However, there is a (potential) issue with this that is quite obvious. Quality stocks tend to trade at high valuation multiples due the fact they: 1. Grow earnings at a high rate 2. Have predictable cash flows This is certainly justified in many instances, but at the same time it can create a double edged sword. Share price growth is a product of growing earnings and multiple expansion. So the moment earnings start to slow down, the multiple can contract immensely. $ZTS is a perfect example of this. They were trading with a PE multiple well above 35 for quite some time but earnings were keeping up. But when earnings dropped, that multiple was no longer justified. The stock has seen its share price nearly half in the last 4 years, and earnings aren't growing fast enough to push it much higher without multiple expansion. When you buy a quality stock... You better be sure it is actually quality.

1 · Reply

ScottSignals2 Feb. 5 at 12:23 PM

$ZTS Accumulation under the radar, breakout above key level could fuel momentum

0 · Reply

ParallelCapital Feb. 4 at 11:29 AM

$ZTS is the animal health leader with strong pharmaceutical and vaccine portfolios; pet care spending is resilient.

0 · Reply

ZacksResearch Feb. 3 at 3:10 PM

Is $ZTS set for another earnings surprise? Zoetis boasts an Earnings ESP of +0.84% and a Zacks Rank #3, with Q4 earnings expected at $1.40 per share and revenues pinned at $2.37 billion. Strong demand for Simparica Trio and dermatology brands could drive revenue higher. See the full analysis here 👉 https://www.zacks.com/stock/news/2827958/5-drugbiotech-stocks-likely-to-outperform-q4-earnings-estimates?cid=sm-stocktwits-2-2827958-body-31690&ADID=SYND_STOCKTWITS_TWEET_2_2827958_BODY_31690

0 · Reply

ZacksResearch Feb. 3 at 2:03 PM

Q4 earnings season — these 5 drug & biotech names could surprise to the upside $ZTS, $PCRX, $APLS, $ACAD, and $DNLI are highlighted as poised to beat on fourth-quarter 2025 earnings, setting up a potential outperformance theme investors should have on their radar. See which drug & biotech stocks could deliver earnings upside 👉 https://www.zacks.com/stock/news/2827958/5-drugbiotech-stocks-likely-to-outperform-q4-earnings-estimates?cid=sm-stocktwits-2-2827958-teaser-31624&ADID=SYND_STOCKTWITS_TWEET_2_2827958_TEASER_31624

0 · Reply

Dondurma Feb. 2 at 5:02 PM

$ZTS interested waiting for under 100

0 · Reply

Market Cap	54.31B
Revenue (ttm)	9.47B
Net Income (ttm)	2.67B
EPS (ttm)	N/A
PE Ratio	19.59
Forward PE	17.92
Profit Margin	28.23%
Debt to Equity Ratio	2.71

Volume	3,024,200
Avg Vol	5,157,208
Day's Range	N/A - N/A
Shares Out	422.13M
Stochastic %K	74%
Beta	0.96
Analysts	Sell
Price Target	$151.13